A short 18 months after its launch as a new company, Microbiotica Ltd has entered into a multi-year collaboration with Genentech, a member of the Roche group, to discover, develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD). Microbiotica was spun out of the Wellcome Trust Sanger Institute in 2016 to research the human microbiome, a term used to describe the genomes of microorganisms in the gut, including at least 1,000 species of bacteria.
